Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E- EPS (ttm)-1.56 Insider Own0.50% Shs Outstand211.12M Perf Week1.81%
Market Cap18.16B Forward P/E121.17 EPS next Y0.71 Insider Trans-3.94% Shs Float210.10M Perf Month-6.41%
Income-313.10M PEG- EPS next Q-0.06 Inst Own97.80% Short Float3.57% Perf Quarter-18.25%
Sales1.54B P/S11.82 EPS this Y-385.10% Inst Trans2.58% Short Ratio4.52 Perf Half Y-29.33%
Book/sh7.72 P/B11.14 EPS next Y121.88% ROA-15.80% Target Price141.89 Perf Year-28.42%
Cash/sh5.54 P/C15.53 EPS next 5Y31.09% ROE-23.30% 52W Range80.85 - 153.15 Perf YTD-9.16%
Dividend- P/FCF- EPS past 5Y-35.00% ROI-14.80% 52W High-43.83% Beta0.62
Dividend %- Quick Ratio4.00 Sales past 5Y38.90% Gross Margin94.80% 52W Low6.41% ATR3.20
Employees1208 Current Ratio4.00 Sales Q/Q36.00% Oper. Margin-15.90% RSI (14)41.48 Volatility4.19% 3.24%
OptionableYes Debt/Eq0.01 EPS Q/Q- Profit Margin-20.40% Rel Volume1.49 Prev Close85.59
ShortableYes LT Debt/Eq0.01 EarningsFeb 15 BMO Payout- Avg Volume1.66M Price86.03
Recom2.00 SMA20-4.22% SMA50-7.89% SMA200-24.49% Volume2,473,819 Change0.51%
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-21-17Reiterated RBC Capital Mkts Sector Perform $136 → $120
Oct-06-17Resumed Goldman Buy $160
Sep-15-17Initiated RBC Capital Mkts Sector Perform $136
Sep-11-17Upgrade Raymond James Mkt Perform → Outperform
Aug-17-17Initiated Evercore ISI In-line $135
May-12-17Initiated Oppenheimer Perform
Apr-17-17Downgrade Piper Jaffray Overweight → Neutral
Apr-10-17Initiated Gabelli & Co Buy $185
Apr-07-17Reiterated Barclays Overweight $135 → $185
Apr-05-17Downgrade Raymond James Outperform → Mkt Perform
Apr-04-17Reiterated RBC Capital Mkts Outperform $138 → $157
Mar-09-17Initiated UBS Neutral $140
Mar-02-17Initiated Instinet Buy $148
Feb-15-17Reiterated RBC Capital Mkts Outperform $123 → $138
Jan-23-17Initiated Credit Suisse Outperform
Oct-12-16Reiterated RBC Capital Mkts Outperform $106 → $113
Sep-29-16Upgrade Raymond James Mkt Perform → Outperform
Aug-10-16Reiterated Leerink Partners Outperform $85 → $95
Aug-10-16Reiterated Barclays Overweight $85 → $100
Feb-15-18 03:09PM  Incyte (INCY) Beats on Q4 Revenues on Strong Jakafi Sales Zacks
08:58AM  Incyte (INCY) Beats on Sales in Q4 Zacks
07:00AM  Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs Business Wire
06:10AM  Incyte Corporation to Host Earnings Call ACCESSWIRE
Feb-14-18 05:01PM  Getting technical: Trading the Chipotle taco-transition gap Yahoo Finance Video
08:56AM  Why Incyte (INCY) Might Surprise This Earnings Season Zacks
Feb-13-18 02:35PM  How is Philadelphia helping lead the war against cancer? American City Business Journals
Feb-12-18 08:56AM  Can Jakafi Performance Drive Incyte's (INCY) Q4 Earnings? Zacks
Feb-06-18 05:45PM  These Biotechs Could Spring Back After Market Correction: Analyst Investor's Business Daily
08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Feb-01-18 08:20AM  Todays Research Reports on Trending Tickers: Incyte Corporation and Intrexon Corporation ACCESSWIRE
Jan-31-18 04:30PM  Incyte Updates Conference Call Time to Report Fourth Quarter and Year-End Financial Results Business Wire
Jan-29-18 04:24PM  5 Health Care Stocks in Gurus' Portfolios GuruFocus.com
Jan-24-18 08:00AM  Incyte to Report Fourth Quarter and Year-End Financial Results Business Wire
Jan-23-18 08:00AM  Incyte Corporation Recommends Shareholders Reject Mini-Tender Offer by TRC Capital Corporation Business Wire
Jan-18-18 09:22AM  Zacks.com highlights: Covanta Holding, Altice USA, Incyte and Archrock Zacks
Jan-17-18 03:14PM  5 Big Biotech Stocks To Buy In 2018 InvestorPlace
Jan-16-18 10:00AM  Will 2018 Be Agenus Inc.'s Best Year Yet? Motley Fool
08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
05:50AM  Concert Pharma shares hit low note on patent challenge denial American City Business Journals
Jan-12-18 03:18PM  Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today Motley Fool
10:34AM  Incyte: S&P 500s Top Loser on January 11 Market Realist
08:20AM  Todays Research Reports on Trending Tickers: Clovis Oncology and Incyte Corporation ACCESSWIRE
Jan-11-18 05:09PM  The Biggest Loser: Incyte Slides 3.7% Barrons.com
Jan-10-18 05:40PM  A Look at Ioniss 3Q17 Revenue Stream Market Realist
10:33AM  Analysts Recommendations for Incyte in January 2018 Market Realist
09:04AM  Incytes Collaborations and Developments in 4Q17 Market Realist
07:36AM  How Incytes Jakafi Performed in 3Q17 Market Realist
Jan-09-18 01:25PM  Assessing Incytes 3Q17 Product Portfolio Market Realist
11:55AM  How Was Incytes Revenue Stream in 3Q17? Market Realist
10:23AM  Examining Incytes Quarterly Revenue Trend Market Realist
10:23AM  Hows Incytes Valuation in January 2018? Market Realist
Jan-08-18 02:30PM  Incyte chief discusses company's latest cancer treatments... CNBC Videos
08:00AM  Incyte and Syros Announce Global Target Discovery and Validation Collaboration Focused on Myeloproliferative Neoplasms Business Wire
Jan-07-18 09:09AM  5 Biggest New Drugs of 2018 -- and How You Can Profit From Their Makers Motley Fool
Jan-05-18 04:39PM  Why These 3 Biotech Stocks Could Outperform Their Peers In 2018 Investor's Business Daily
Jan-03-18 06:29PM  Is Incyte Corporations (NASDAQ:INCY) CEO Paid Enough To Stay Motivated? Simply Wall St.
03:25PM  Analysts Take Action on Health Care Stocks GuruFocus.com
Dec-22-17 06:04AM  3 Promising Cancer Immunotherapies to Watch in 2018 Motley Fool
Dec-20-17 08:00AM  8 Stocks That Can Outperform Amid Low Volatility: Goldman Investopedia
Dec-15-17 09:43AM  Zacks.com featured highlights: Incyte, AMC Entertainment, Mercadolibre, PTC and Clean Harbors Zacks
Dec-14-17 09:10AM  Dispose of These 5 Toxic Stocks or Sell Short for Gains Zacks
08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Dec-11-17 10:02AM  Incyte (INCY) Reports Phase III Follow-Up Data for Jakafi Zacks
09:40AM  3 Stocks in Focus as Biotech M&A Hopes for 2018 Rise Zacks
08:20AM  4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018 Zacks
Dec-10-17 07:31AM  Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi® (ruxolitinib) in Patients with Polycythemia Vera Business Wire
Dec-04-17 09:03AM  What Analysts Recommend for United Therapeutics in November 2017 Market Realist
08:01AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Dec-01-17 08:04AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-30-17 08:05AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-28-17 11:58AM  Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte Forbes
Nov-21-17 11:56AM  ETFs with exposure to Incyte Corp. : November 21, 2017 Capital Cube
08:30AM  Six promising stocks to buy for the biotech rebound ahead MarketWatch
08:20AM  Todays Research Reports on Trending Tickers: Incyte Corporation and Repros Therapeutics Inc. ACCESSWIRE
Nov-20-17 06:54PM  Is Incyte Corporations (INCY) Liquidity As Good As Its Solvency? Simply Wall St. -6.18%
08:07AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-16-17 07:55AM  Incyte (INCY) Initiates Essential Thrombocythemia Trial Zacks
Nov-15-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
08:00AM  Investor Expectations to Drive Momentum within Barracuda Networks, Abraxas Petroleum, Vertex Pharmaceuticals, Incyte, Forum Energy, and S&P Global Discovering Underlying Factors of Influence GlobeNewswire
07:30AM  Incyte Announces Initiation of Pivotal Clinical Trial of Ruxolitinib (Jakafi®) for the Treatment of Essential Thrombocythemia Business Wire
Nov-14-17 08:03AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
Nov-07-17 07:07PM  Cramer's lightning round: Don't give up on Incyte CNBC Videos
06:52PM  Cramer's lightning round: Don't give up on Incyte CNBC
07:30AM  Featured Company News - Alnylam Shares Positive Preliminary Results from Ongoing Phase-1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 ACCESSWIRE
Nov-06-17 11:49AM  ETFs with exposure to Incyte Corp. : November 6, 2017 Capital Cube
10:48AM  The Week Ahead: Earnings Season Continues, Several IPOs, Notable Conferences On The Docket Benzinga
Nov-05-17 09:00AM  ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo PR Newswire
Nov-04-17 12:02PM  November Top Growth Stocks Simply Wall St.
Nov-03-17 10:05AM  Incyte Corp. :INCY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
Nov-01-17 03:05PM  Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal Zacks
01:56PM  Edited Transcript of INCY earnings conference call or presentation 31-Oct-17 2:00pm GMT Thomson Reuters StreetEvents
11:14AM  More Than 30 Abstracts Highlighting Data from Incytes Portfolio Accepted for Presentation at the 59th Annual ASH Meeting Business Wire
09:24AM  Biotech Stock Roundup: Celgene, Amgen, Gilead Hit by Q3 Results, Vertex Beats on All Fronts Zacks
08:20AM  Today's Research Reports on Stocks to Watch: Incyte Corporation and Array BioPharma ACCESSWIRE
Oct-31-17 04:31PM  Incyte Rises On A Beat-And-Raise, Expanding Deal With AstraZeneca Investor's Business Daily
04:00PM  Incyte, AstraZeneca expand collaboration on potential lung cancer therapy American City Business Journals
09:26AM  Geron Shares Rise on Fast Track Designation -- Biotech Movers TheStreet.com
07:55AM  Incyte Corporation to Host Earnings Call ACCESSWIRE
07:45AM  Incyte tops Street 3Q forecasts Associated Press
07:05AM  What Does Incyte Corporations (INCY) Share Price Indicate? Simply Wall St.
07:00AM  Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs Business Wire
04:43AM  AstraZeneca plans new pivotal lung cancer trial with Incyte Reuters
03:00AM  Incyte and AstraZeneca to Enter Clinical Trial Collaboration in Early Lung Cancer Business Wire
Oct-30-17 04:30PM  Incyte Names New Member to Its Board of Directors Business Wire
10:41AM  What's in the Cards for PFE, INCY and ACOR in Q3 Earnings? Zacks
08:15AM  Zacks.com featured highlights: Incyte, Apache, Titan International, AMC Entertainment and Carbonite Zacks
Oct-27-17 09:35AM  Get Rid of These 5 Toxic Stocks or Sell Short for Profit Zacks
08:48AM  Why Incyte (INCY) Might Surprise This Earnings Season Zacks
Oct-26-17 03:10PM  Why this Rockville biotech's stock made a big jump this week American City Business Journals
Oct-25-17 06:07PM  Why MacroGenics, Inc. Stock Soared Today Motley Fool
01:00PM  Incyte enters into licensing deal valued at up to $900M American City Business Journals
09:28AM  MacroGenics Soars on Collaboration with Incyte -- Biotech Movers TheStreet.com
06:45AM  Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012 Business Wire
Oct-24-17 10:57AM  Is a Beat in Store for Alexion (ALXN) This Earnings Season? Zacks
10:03AM  Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco Zacks
08:02AM  See what the IHS Markit Score report has to say about Incyte Corp. Markit
08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Oct-23-17 02:30PM  How Earnings Will Fuel Biotech's Bull Run: BMO Capital Investopedia
Oct-20-17 02:39PM  Gilead Sciences Stock: Performance in 3Q17 Market Realist
Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology in the United States and internationally. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. The company's clinical stage products include ruxolitinib cream that is in Phase II clinical trial for the treatment of alopecia areata and atopic dermatitis; and baricitinib, which is in Phase III clinical trial for treatment of rheumatoid arthritis. In addition, it is developing itacitinib that is in Phase I/II clinical trials in combination with osimertinib for non-small cell lung cancer (NSCLC); INCB52793, INCB54329 (BRD), INCB57643 (BRD), and INCB53914 (PIM), which are in Phase I/II trials for the treatment of advanced malignancies; INCB54828 (FGFR1/2/3) that is in Phase II clinical trial the treatment of bladder cancer, cholangiocarcinoma, and 8p11 MPNs; INCB59872 (LSD1), which is in Phase II clinical trial the treatment of acute myeloid leukemia and small cell lung cancer; and capmatinib that is in Phase II clinical trial for the treatment of NSCLC and liver cancer. Further, the company's clinical stage products include epacadostat, which is in Phase II clinical trial for the treatment of various tumors, and in Phase I/II clinical trials for the treatment of NSCLC and bladder cancer, as well as in Phase III clinical trial for the treatment of advanced melanoma; and INCB01158, INCSHR1210, INCAGN1876 (GITR), and INCAGN1949 (OX40), which are in Phase I/II clinical trials for the treatment of solid tumors. It markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. The company has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer Inc; and Abramson Cancer Center. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRYSKA DAVID WExecutive Vice President, CFOJan 05Option Exercise83.836,760566,69120,752Jan 09 04:09 PM
GRYSKA DAVID WExecutive Vice President, CFOJan 05Sale98.876,760668,36113,992Jan 09 04:09 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Option Exercise72.865,000364,30013,676Jan 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 02Sale97.265,000486,3008,676Jan 03 04:32 PM
Huber Reid MEVP, Chief Scientific OfficerDec 01Sale98.0169668,21538,205Dec 05 04:01 PM
FRIEDMAN PAUL ADirectorNov 16Sale105.2428,5073,000,077269,011Nov 20 04:25 PM
GRYSKA DAVID WExecutive Vice President, CFONov 02Sale105.633,915413,54113,992Nov 03 04:01 PM
Hoppenot HerveChairman / CEOSep 18Sale119.4570,5028,421,464299,004Sep 20 04:28 PM
Flannelly Barry PEVP & General Manager USSep 14Sale124.2571488,71514,782Sep 15 04:11 PM
BAKER BROS. ADVISORS LPDirectorSep 08Buy132.00100,00013,200,00029,247,347Sep 08 05:06 PM
Trower PaulPrincipal Accounting OfficerSep 05Option Exercise17.793,00053,37014,853Sep 07 04:04 PM
Trower PaulPrincipal Accounting OfficerSep 05Sale138.413,000415,23011,853Sep 07 04:04 PM
Siegel Eric H.EVP, General CounselSep 01Option Exercise64.551,820117,48123,553Sep 05 04:27 PM
Siegel Eric H.EVP, General CounselSep 01Sale137.401,820250,06821,733Sep 05 04:27 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Option Exercise17.7920,000355,80055,067Sep 05 04:22 PM
SWAIN PAULA JEVP, Human ResourcesAug 31Sale140.0020,0002,800,00035,067Sep 05 04:22 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Option Exercise89.522,111188,97420,276Aug 31 04:13 PM
Stein Steven HEVP & Chief Medical OfficerAug 29Sale125.002,111263,87518,165Aug 31 04:13 PM
Trower PaulPrincipal Accounting OfficerAug 04Option Exercise17.793,00053,37014,853Aug 07 04:33 PM
Trower PaulPrincipal Accounting OfficerAug 04Sale125.253,000375,75011,853Aug 07 04:33 PM
Siegel Eric H.EVP, General CounselAug 01Option Exercise64.551,820117,48123,553Aug 03 04:54 PM
Siegel Eric H.EVP, General CounselAug 01Sale132.921,820241,91421,733Aug 03 04:54 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Option Exercise85.686,485555,64124,650Jul 21 04:01 PM
Stein Steven HEVP & Chief Medical OfficerJul 20Sale131.096,485850,11918,165Jul 21 04:01 PM
Trower PaulPrincipal Accounting OfficerJul 05Option Exercise17.793,00053,37015,148Jul 07 05:02 PM
Trower PaulPrincipal Accounting OfficerJul 05Sale126.183,000378,54012,148Jul 07 05:02 PM
Siegel Eric H.EVP, General CounselJul 03Option Exercise64.551,820117,48120,036Jul 05 06:20 PM
Siegel Eric H.EVP, General CounselJul 03Sale126.201,820229,68418,216Jul 05 06:20 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Option Exercise73.2159943,85319,614Jul 05 04:12 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 30Sale129.7459977,71419,015Jul 05 04:12 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Option Exercise91.459,883903,82424,531Jun 22 04:29 PM
Stein Steven HEVP & Chief Medical OfficerJun 20Sale125.009,8831,235,37514,648Jun 22 04:29 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Option Exercise73.2116,7561,226,70735,771Jun 14 04:50 PM
GRYSKA DAVID WExecutive Vice President, CFOJun 12Sale116.6016,7561,953,75019,015Jun 14 04:50 PM
Siegel Eric H.EVP, General CounselJun 06Option Exercise66.661,29286,12718,216Jun 07 04:21 PM
Trower PaulPrincipal Accounting OfficerJun 05Option Exercise17.793,00053,37013,950Jun 07 04:12 PM
Trower PaulPrincipal Accounting OfficerJun 05Sale132.503,000397,50010,950Jun 07 04:12 PM
Siegel Eric H.EVP, General CounselJun 01Option Exercise64.551,820117,48118,744Jun 02 04:22 PM
Siegel Eric H.EVP, General CounselJun 01Sale130.001,820236,60016,924Jun 02 04:22 PM
BIENAIME JEAN JACQUESDirectorMay 31Buy131.8050065,9004,677Jun 02 04:14 PM
BIENAIME JEAN JACQUESDirectorMay 15Buy115.0050057,5004,177May 17 04:18 PM
Huber Reid MEVP, Chief Scientific OfficerMay 08Sale119.218,5771,022,46436,037May 09 04:38 PM
Trower PaulPrincipal Accounting OfficerMay 05Option Exercise17.793,00053,37013,950May 09 04:17 PM
Trower PaulPrincipal Accounting OfficerMay 05Sale121.703,000365,10010,950May 09 04:17 PM
Siegel Eric H.EVP, General CounselMay 01Option Exercise64.551,820117,48118,744May 02 05:52 PM
Flannelly Barry PEVP & General Manager USMay 01Option Exercise48.442,06499,98017,949May 02 06:01 PM
Siegel Eric H.EVP, General CounselMay 01Sale124.731,820227,00916,924May 02 05:52 PM
Flannelly Barry PEVP & General Manager USMay 01Sale124.735,296660,56412,653May 02 06:01 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 28Option Exercise67.061,38993,14620,404May 02 05:39 PM
BIENAIME JEAN JACQUESDirectorApr 28Buy124.2650062,1303,677May 02 04:31 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 28Sale124.261,389172,59719,015May 02 05:39 PM
BAKER BROS. ADVISORS LPDirectorApr 27Option Exercise7.2660,000435,60029,161,795Apr 28 05:10 PM
BIENAIME JEAN JACQUESDirectorApr 13Buy139.661,000139,6603,177Apr 17 04:56 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 10Option Exercise67.0641,5282,784,86860,543Apr 11 04:14 PM
Siegel Eric H.EVP, General CounselApr 10Option Exercise39.134,043158,20620,828Apr 11 04:19 PM
GRYSKA DAVID WExecutive Vice President, CFOApr 10Sale138.0041,5285,730,86419,015Apr 11 04:14 PM
Siegel Eric H.EVP, General CounselApr 10Sale140.184,043566,74816,785Apr 11 04:19 PM
Stein Steven HEVP & Chief Medical OfficerApr 07Option Exercise89.7932,0002,873,16046,648Apr 11 04:24 PM
BIENAIME JEAN JACQUESDirectorApr 07Buy139.481,000139,4802,177Apr 11 04:06 PM
Stein Steven HEVP & Chief Medical OfficerApr 07Sale137.8832,0004,412,31014,648Apr 11 04:24 PM
FRIEDMAN PAUL ADirectorMar 17Option Exercise18.3241,693763,816339,211Mar 20 04:10 PM
BROOKE PAUL ADirectorMar 17Option Exercise7.2620,000145,200216,756Mar 20 04:14 PM
FRIEDMAN PAUL ADirectorMar 17Sale148.1841,6936,178,069297,518Mar 20 04:10 PM
BROOKE PAUL ADirectorMar 17Sale147.7520,0002,955,000196,756Mar 20 04:14 PM
FRIEDMAN PAUL ADirectorMar 16Option Exercise18.328,307152,184305,825Mar 20 04:10 PM
FRIEDMAN PAUL ADirectorMar 16Sale151.458,3071,258,095297,518Mar 20 04:10 PM
Huber Reid MEVP, Chief Scientific OfficerFeb 27Sale131.882,008264,81552,262Mar 01 04:56 PM
FRIEDMAN PAUL ADirectorFeb 23Option Exercise18.3250,000916,000347,518Feb 27 04:54 PM
FRIEDMAN PAUL ADirectorFeb 23Sale120.3250,0006,016,000297,518Feb 27 04:54 PM